Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States)

Cancer Causes and Control

Volumn 9, Issue 1, 1998, Pages 83-88

  Rosenberg, Lynn ^a   Rao, R Sowmya ^a   Palmer, Julie R ^a   Strom, Brian L ^b   Zauber, Ann ^c   Warshauer, M Ellen ^d   Stolley, Paul D ^e   Shapiro, Samuel ^a  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acetaminophen; Kidney neoplasms; Renal cell carcinoma; United States

Indexed keywords

PARACETAMOL;

ARTICLE; CANCER CONTROL; CONTROLLED STUDY; DRUG SAFETY; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY TUMOR; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; UNITED STATES; URINARY TRACT;

ACETAMINOPHEN; ADULT; AGED; ANALGESICS, NON-NARCOTIC; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; UNITED STATES; UROLOGIC NEOPLASMS;

EID: 15444347629     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008805505154     Document Type: Article

References (23)

1. International Agency for Research on Cancer. Some Pharmaceutical Drugs. Lyon, France: IARC, 1980; IARC Monogr Eval Carcinog Risk Chem Humans, Vol. 24: 135-61.
2. International Agency for Research on Cancer. Some Pharmaceutical Drugs. Lyon, France: IARC, 1980; IARC Monogr Eval Carcinog Risk Chem Humans, Vol. 24: 135-61.
3. International Agency for Research on Cancer. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. Lyon, France: IARC, 1987; IARC Monogr Eval Carcinog Risk Chem Humans Suppl. 7: 310-2.
4. International Agency for Research on Cancer. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. Lyon, France: IARC, 1987; IARC Monogr Eval Carcinog Risk Chem Humans Suppl. 7: 310-2.
5. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985; 313: 292-5.
6. Stolley PD. The risks of phenacetin use. N Engl J Med 1991; 324: 191-3.
7. Derby LE, Jick H. Acetaminophen and renal and bladder cancer. Epidemiology 1996; 7: 358-62.
8. Shapiro S. Case-control surveillance. In: Strom BL, ed. Pharmacoepidemiology, 2nd Edition. Chichester, UK: John Wiley and Sons, 1994: 301-22.
9. Schlesselman JS. Case-control Studies: Design, Conduct, Analysis. New York, NY (USA): Oxford University Press, 1982.
10. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: NSAIDs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83: 355-8.
11. Berkel HJ, Holcombe RF, Middlebrooks M, Kannan K. Nonsteroidal antiinflammatory drugs and colorectal cancer. Epidemiol Rev 1996; 18: 205-17.
12. International Agency for Research on Cancer. Pharmaceutical Drugs. Lyon, France: IARC, 1990; IARC Monogr Eval Carcinog Risks Humans, Vol. 50: 307-32.
13. International Agency for Research on Cancer. Pharmaceutical Drugs. Lyon, France: IARC, 1990; IARC Monogr Eval Carcinog Risks Humans, Vol. 50: 307-32.
14. 1 mice (feed studies). National Toxicology Program: Technical Report Series No. 394. US Department of Health and Human Services.
15. McLaughlin JK, Blot WJ, Mandel JS, Schuman LM, Mehl ES, Fraumeni JF Jr. Etiology of cancer of the renal pelvis. J Natl Cancer Inst 1983; 71: 287-91.
16. McCredie M, Stewart JH, Day NE. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer 1993; 53: 245-9.
17. Ross RK, Paganini-Hill A, Landolf J, Gerkens V, Henderson BE. Analgesics, cigarette smoking, and other risk factors for cancer of the renal pelvis and ureter. Cancer Res 1989; 49: 1045-8.
18. Steineck G, Wiholm BE, DeVerdier MG. Acetaminophen, some other drugs, some diseases, and risk of transitional cell carcinoma. Acta Oncologica 1995; 34: 741-8.
19. Linet MS, Chow WH, McLaughlin JK, et al. Analgesics and cancers of the renal pelvis and ureter. Int J Cancer 1995; 62: 15-18.
20. McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JF Jr. A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst 1984; 72: 275-84.
21. McLaughlin JK, Gao VT, Gao RN, et al. Risk factors for renal-cell cancer in Shanghai China. Int J Cancer 1992; 52: 562-5.
22. Krieger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 1993; 4: 101-10.
23. McCredie M, Pommer W, McLaughlin JK, et al. International renal-cell cancer study. II. Analgesics. Int J Cancer 1995; 60: 345-9.